NLRP3 and Alzheimer disease: Therefore, we set out to explore the therapeutic benefit of targeting NLRP3 in 4-month-old 5XFAD/Rubicon KO mice with established cognitive impairment (Supplementary Fig. 2) as well as confirmed AD pathology32.